{"id":"de-108","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Ocular discomfort"}]},"_chembl":{"chemblId":"CHEMBL3663413","moleculeType":"Small molecule","molecularWeight":"423.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DE-108 works as a ROCK inhibitor, which relaxes the trabecular meshwork and Schlemm's canal tissues in the eye, thereby improving aqueous humor drainage and lowering intraocular pressure. This mechanism is distinct from traditional glaucoma therapies and represents a novel approach to managing elevated intraocular pressure in glaucoma and ocular hypertension patients.","oneSentence":"DE-108 is a small molecule that inhibits Rho-associated protein kinase (ROCK) to reduce intraocular pressure by decreasing aqueous humor outflow resistance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:26.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma and ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02573610","phase":"PHASE3","title":"Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2015-09-21","conditions":"Cataract Surgery","enrollment":576}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Levofloxacin"],"phase":"phase_3","status":"active","brandName":"DE-108","genericName":"DE-108","companyName":"Santen Pharmaceutical Co., Ltd.","companyId":"santen-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DE-108 is a small molecule that inhibits Rho-associated protein kinase (ROCK) to reduce intraocular pressure by decreasing aqueous humor outflow resistance. Used for Glaucoma and ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}